Aller au contenu

Marilyne Labrie

Professeure, Faculté de médecine et des sciences de la santé
FMSS Dép. d'immunologie et de biologie cellulaire


Sujet de recherche

Cancer of the Reproductive System

Disciplines de recherche

Biology and Related Sciences


Ovarian cancer, Adaptive resistance, Targeted therapy, Single-cell proteomics, multi-omics

Intérêts de recherche

My research program aims at improving women's health by investigating how cancer cells from aggressive women's tumors progress and how they adapt to cancer therapy. By understanding how tumors develop adaptive resistance to therapy we can develop combination therapy approaches that will improve the outcome of these patients.

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français, Espagnol (castillan)


(2021). (Post-doctorate, Post-doctorate).

(2018). (Post-doctorate, Post-doctorate).

(2016). Les galectines: biomarqueurs et cibles thérapeutiques dans le cancer (Doctorate, PhD in Immunology and Virology). INRS-Institute Armand Frappier.

(2012). (Master's Thesis, MSc in Biology). Université du Québec à Montréal.

(2010). (Bachelor's, BSc in Biology). Université du Québec à Montréal.

Expérience académique

Assistant professor. (2021-). Université de Sherbrooke. Canada.

Postdoctoral Fellow. (2018-2021).

Postdoctoral Fellow. (2016-2018).

Ph.D. Student. (2011-2016). INRS-Institute Armand Frappier. Canada.

M.Sc. Student. (2009-2011). Université du Québec à Montréal. Canada.

Teacher Assistant (BIA2201). (2009-2011). Université du Québec à Montréal. Canada.

Teacher Assistant (BIA1000). (2009-2010). Université du Québec à Montréal. Canada.

Summer Student. (2009-2009). Université du Québec à Montréal. Canada.

Prix et distinctions

  • (2019) AACR scholar in training award. AACR. (Prize / Award).
  • (2016) PhD Fellowship. Fonds de recherche du Québec - Santé (FRQS). (Distinction).
  • (2016) Biomed best oral presentation. Biomed. (Prize / Award).
  • (2016) CIHR travel award. CIHR. (Prize / Award).
  • (2015) Canadian cancer research alliance travel award. Canadian cancer research alliance. (Prize / Award).


  • Grant. (Under Review). Principal Applicant. Building of a functional single cell proteomics resource for the study the DNA damage response. Natural Sciences and Engineering Research Council of Canada (NSERC). Discovery Grants Program. 200 000 $. (2022-2027)
  • Research Chair. (Under Review). Principal Applicant. Tier 2 Canada Research Chair. Canada Research Chairs (CRC). 600 000 $. (2022-2027)
  • Grant. (Awarded). Principal Applicant. 2021 OCC/OvCAN-CRS Strategic Partnership Grant Competition. Cancer Research Society (The). 225 000 $. (2021-2023)
  • Grant. (Awarded). Co-applicant. Développement d’une approche de détection des cellules T helper périphériques dans les tissus de cancer traitable par une immunothérapie. Institut de recherche sur le cancer de l'Université de Sherbrooke. Projets pilotes collaboratifs 2021. 15 000 $. (2022-2022)
  • Grant. (Under Review). Principal Applicant. CFI - John R. Evans Leaders Fund. Canada Foundation for Innovation (CFI). John R. Evans Leaders Fund. 450 000 $. (2022)
  • Grant. (Completed). Principal Investigator. Ann and Sol Schreiber Mentored Investigator Award (Ovarian cancer research alliance - OCRA). Ovarian Cancer Research Alliance. Ann and Sol Schreiber Mentored Investigator Award. 75 000 $. (2019-2021)


Articles de revue

  • Shengnan Yu, Shiyou Wei, Milan Savani, Xiang Lin, Kuang Du, Ilgen Mender, Silvia Siteni, Themistoklis Vasilopoulos, Zachary J Reitman, Yin Ku, Di Wu, Hao Liu, Meng Tian, Yaohui Chen, Marilyne Labrie, Casey M Charbonneau, Eric Sugarman, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Wen Jiang, Roger E McLendon, Edward Pan, Mustafa Khasraw, Kyle M Walsh, Yiling Lu, Meenhard Herlyn, Gordon Mills, Utz Herbig, Zhi Wei, Stephen T Keir, Keith Flaherty, Lunxu Liu, Kongming Wu, Jerry W Shay, Kalil Abdullah, Gao Zhang, David M Ashley. (2021). A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas. Clinical Cancer Research (Published).
  • Johnson B, Creason AL, Stommel JM, KeckJ, Parmar S, Betts CB, Blucher A, Boniface C, Bucher E, Burlingame E, Chin K, Eng J, Feiler HS, Kolodzie A, Kong B, Labrie M, Leyshock P, Mitri S, PattersonJ, Riesterer JL, Sivagnanam S, Sudar D, Thibault G, Zheng C, Nan X, Heiser LM, Spellman PT, Thomas G, Demir E, Chang YH, Coussens LM, Guimaraes AR, Corless C, Goecks J, Bergan R, Mitri Z, Mills GB, Gray JW. (2021). AnIntegrated Clinical, Omic, and Image Atlas of an Evolving Metastatic BreastCancer. Cell Reports Medicine (Submitted).
  • Shiyou Wei, Delong Yin, Shengnan Yu, Xiang Lin, Milan Savani, Kuang Du, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Stephen Keir, Eric Sugarman, Marilyne Labrie, Yiling Lu, Gordon Mills, Meenhard Herlyn, Kongming Wu, Lunxu Liu, Zhi Wei, Kalil Abdullah, Gao Zhang, and David Ashley. (2021). Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas. Clinical Cancer Research (Submitted).
  • Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, Johnson BE, Downey M, Thomas G, Beadling C, Heiser LM, Kolodzie A, Guimaraes AR, Corless CL, Gray JW, Mills GB, Bergan RC, Mitri ZI. (2021). Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ Precision Oncology (Published).
  • Parmar S, Keck JM, Kong B, Look R, Johnson B, Patterson J, Labrie M, Guimaraes AR, Corless CL, Beadling C, Kolodzie A, Bergan R, Gray JW, Mills GB, Mitri ZI. (2021). Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer. JCO Precision Oncology (Published).
  • Liu X, Ge Z, Yang F, Contreras A, Lee S, White J, Lu Y, Labrie M, Arun B, Moulder S, Mills GB, Piwnica-Worms H, Litton J, Chang J. (2021). Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. Journal of Clinical Investigation (Submitted).
  • Luke Ternes , Mark Dane , Sean Gross , Marilyne Labrie , Gordon Mills , Joe Gray , Laura Heiser, Young Hwan Chang. (2021). ME-VAE: Multi-Encoder Variational AutoEncoder for Controlling Multiple Transformational Features in Single Cell Image Analysis. Guided Open Access (Submitted).
  • Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI. (2021). Multi-omics analysis of serial samples frommetastatic TNBC patients on PARP inhibitor monotherapy provide insight intorational PARP inhibitor therapy combinations. NPJ Precision Oncology (Published).
  • Westin SN§, Labrie M§ Blucher A, Creason A, Fang Y, Vellano C, Kim TB, Lee S, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB (§:Co-first author). (2021). Phase1b dose expansion and translational analyses of olaparib in combination withthe oral AKT inhibitor capivasertib in recurrent endometrial, triple negativebreast, and ovarian, primary peritoneal, or fallopian tube cancer. Clinical Cancer Research (Published).
  • Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, XiaoM, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Cheng C, Rebecca VW, Wei Z, Lu Y, Mills GB, Xu X, Herlyn M, Guo W. (2021). Targetingthe mTOR Signaling Axis Overcomes Acquired Resistance to Combined BRAF and MEKInhibition in BRAF-Mutant Melanoma. Oncogene (In Press).
  • Labrie M, Brugge J, Mills GB, Zervantonakis I. (2021). Therapeutic opportunities engendered by adaptive responses to targeted therapies in cancer. Nature Review Cancer (Accepted).
  • Sun C, Fang Y, Labrie M, Li X, Mills GB. (2020). Systems approach to rational combination therapy: PARP inhibitors. Biochem Soc Trans (Published).
  • Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. (2019). Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget (Published).
  • Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. (2019). PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Research (Published).
  • Labrie M, Kendsersky ND, Ma H, Campbell L, Eng J, Chin K, Mills GB. (2019). Proteomics advances for precision therapy in ovarian cancer. Expert Rev Proteomics (Published).
  • Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. (2019). Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell (Published).
  • Labrie M, Fang Y, Kendsersky ND, Li J, Liang H, Westin SN, Mitri, Z, Mills GB. (2019). Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. Adv Exp Med Biol (Published).
  • Peng X, Xu X, Wang Y, Hawke DH, Yu S, Han L, Zhou Z, Mojumdar K, Jeong KJ, Labrie M, Tsang YH, Zhang M, Lu Y, Hwu P, Scott KL, Liang H, Mills GB. (2018). A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. Cancer cell (Published).
  • Lai H, Zhao X, Qin Y, Ding Y, Chen R, Li G, Labrie M, Ding Z, Zhou J, Hu J, Ma D, Fang Y, Gao Q. (2018). FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer. J Exp Clin Cancer Res (Published).
  • Labrie M, Fernandes De Araujo LO, Communal L, Mes-Masson AM, St-Pierre Y. (2017). Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Scientific Reports (Published).
  • Grosset AA, Labrie M, Vladoiu MC, Yousef EM, Gaboury L, St-Pierre y. (2016). Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets. Oncotarget (Published).
  • Labrie M, Vladoiu M, Leclerc BG, Grosset AA, Gaboury L, Stagg J and St-Pierre Y. (2015). A mutation in the carbohydrate recognition domain drives a phenotypicswitch in the role of galectin-7 in prostate cancer. Plos One 10 (7), e0131307. (Published).
  • Labrie M, Lalonde M, Najyb O, Thiery M, Daneault C, Des Rosiers C, Rassart E and Mounier C. (2015). Apolipoprotein D Transgenic Mice Develop Hepatic Steatosis through Activation of PPARγ and Fatty Acid Uptake. Plos One 10 (6), e0130230. (Published).
  • Vladoiu MC, Labrie M, Létourneau M, Egesborg P, Gagné D, Billard E, Grosset AA, Doucet N, Chatenet D & St-Pierre Y. (2015). Design of a peptidic inhibitor that targets the dimer interface of aprototypic galectin. Oncotarget 6 (38), 40970-80. (Published).

Autres contributions

Cours enseignés

  • BIA1000 - Échantillonnage et observations sur le terrain. (2009-08-01 à 2010-09-01).
  • BIA2201 - Régulation animale et humaine. BIA2201. (2009-01-06 à 2011-04-06).


  • (2021). Adaptive responses of aggressive cancers to PARP inhibitor-based therapies. Recruitment Seminar - Centre de Recherche de l’Université de Sherbrooke (CRCHUS). Canada
  • (2021). Adaptive responses of aggressive cancers to PARP inhibitor-based therapies. First recruitment Seminar - Centre de Recherche du Centre Hospitalier de l’Université de Montréal (Cancer Axis). Canada
  • (2021). Adaptive responses of aggressive cancers to PARP inhibitor-based therapies. Second Recruitment Seminar - Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM) (Cancer Axis). Canada
  • (2021). Adaptive responses of ovarian cancer to therapeutic stresses. Research Seminar - Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM) (Gyneco-Oncology department). Canada
  • (2021). Unraveling molecular mechanisms of ovarian cancer brain metastases development through spatially resolved multi-omics analysis. CTD2 onsite visit. United States
  • Gordon B. Mills, Joan Brugge, Ioannis Zervantonakis. (2020). Targeting adaptive responses in cancer. San Antonio Breast Cancer Symposium, Online symposium. United States
  • (2019). How to improve the treatment of ovarian cancer patients with PARP inhibitors. Ovarian cancer alliance of Oregon and southwest Washington annual luncheon. Portland, United States
  • (2019). Proteomics approaches to study the adaptive responses of ovarian tumors to PARP inhibitor. CTD2 onsite visit. Portland, United States
  • (2019). RPPA technology and analytics overview. OMS Atlas/SMMART retreat. Portland, United States
  • (2019). Single cell proteomic analysis of tumoral heterogeneity in response to PARP inhibitor. AACR – Advances in ovarian cancer research. Atlanta, United States
  • (2018). Window of opportunity trial: assessing the adaptive response of HGSOC to PARPi for informed combination therapies. 12th Biennial Ovarian Cancer Research Symposium. Seattle, United States
  • (2017). Adaptive response of ovarian cancer cells to PARP and DNA damage checkpoint inhibitors. Northwest Gynecological Cancer Symposium. Seattle, United States
  • (2016). Expression of galectins in high grade serous ovarian cancer. AACR Annual meeting. New Orleans, United States
  • (2016). Galectins as biomarkers in high grade serous ovarian cancer. Atlantic-Quebec workshop for next-gen researcher. Montreal, Canada
  • Communal L, Grosset AA, Gaboury L, Mes-Masson AM and St-Pierre Y. (2015). Galectinomics: the road towards the development of new ovarian cancer biomarkers. Canadian cancer research conference. Canada
  • (2015). Treatment of cancer: Towards a personalized approach. Health in Innovation Symposium. Canada
  • (2015). Using databases for the identification of novel predictive biomarkers in ovarian cancer. Atelier Biomed. Canada